The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the importance of proactively reassessing treatment in patients with myelofibrosis who have an inadequate response to JAK inhibitors. He highlights the need to consider treatment switching when spleen response and symptom control remain suboptimal or anemia and thrombocytopenia develop, rather than waiting until the disease is more advanced. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
